Development-stage Biolink promotes dialysis access device as likely to make substantial savings
This article was originally published in Clinica
Executive Summary
Biolink, a five-year old US development-stage company, is attempting to remove the problems associated with vessel exhaustion in haemodialysis. Its device looks likely to reduce patient costs, cut down hospitalisation and even prevent infection-related deaths, by adapting concepts from oncology practice.
You may also be interested in...
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.